CN113354713A - Polypeptide and application thereof in preparation of platelet aggregation resisting medicines - Google Patents
Polypeptide and application thereof in preparation of platelet aggregation resisting medicines Download PDFInfo
- Publication number
- CN113354713A CN113354713A CN202110664292.9A CN202110664292A CN113354713A CN 113354713 A CN113354713 A CN 113354713A CN 202110664292 A CN202110664292 A CN 202110664292A CN 113354713 A CN113354713 A CN 113354713A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- platelet aggregation
- preparation
- application
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 66
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 66
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 66
- 208000010110 spontaneous platelet aggregation Diseases 0.000 title claims abstract description 54
- 239000003814 drug Substances 0.000 title claims description 19
- 238000002360 preparation method Methods 0.000 title claims description 19
- 229940079593 drug Drugs 0.000 title claims description 10
- 108090000190 Thrombin Proteins 0.000 claims abstract description 23
- 229960004072 thrombin Drugs 0.000 claims abstract description 23
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 20
- 230000000702 anti-platelet effect Effects 0.000 claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 12
- 102000008186 Collagen Human genes 0.000 claims abstract description 7
- 108010035532 Collagen Proteins 0.000 claims abstract description 7
- 229920001436 collagen Polymers 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 231100000673 dose–response relationship Toxicity 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 5
- 239000012190 activator Substances 0.000 abstract description 2
- 238000012544 monitoring process Methods 0.000 abstract description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 abstract 1
- 229930182837 (R)-adrenaline Natural products 0.000 abstract 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 abstract 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 abstract 1
- 108010081391 Ristocetin Proteins 0.000 abstract 1
- 229940114079 arachidonic acid Drugs 0.000 abstract 1
- 235000021342 arachidonic acid Nutrition 0.000 abstract 1
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 abstract 1
- 229960005139 epinephrine Drugs 0.000 abstract 1
- 229950004257 ristocetin Drugs 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 8
- 238000004220 aggregation Methods 0.000 description 8
- 229940127218 antiplatelet drug Drugs 0.000 description 7
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000007347 Apyrase Human genes 0.000 description 2
- 108010007730 Apyrase Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101001098529 Homo sapiens Proteinase-activated receptor 1 Proteins 0.000 description 2
- 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000878457 Macrocallista nimbosa FMRFamide Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 101710121440 Proteinase-activated receptor 1 Proteins 0.000 description 1
- OOKCGAYXSNJBGQ-ZLUOBGJFSA-N Ser-Asn-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OOKCGAYXSNJBGQ-ZLUOBGJFSA-N 0.000 description 1
- DKKGAAJTDKHWOD-BIIVOSGPSA-N Ser-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)C(=O)O DKKGAAJTDKHWOD-BIIVOSGPSA-N 0.000 description 1
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100036862 Solute carrier family 52, riboflavin transporter, member 2 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GBESYURLQOYWLU-LAEOZQHASA-N Val-Glu-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N GBESYURLQOYWLU-LAEOZQHASA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a polypeptide A11 for resisting platelet aggregation, belonging to the technical field of medical biology. The polypeptide A11 of the invention is a sequence of polypeptide consisting of 12 amino acids and having SEQ ID NO. 1, the molecular weight is 1262.24, and the sequence is Ser-Ile-Ser-Ser-Asn-Asn-Ser-Asn-Pro-Val-Glu-Asp. The polypeptide is not limited to inhibiting thrombin-induced platelet aggregation, can be used for exploring the influence of the polypeptide and other platelet activators (collagen, arachidonic acid, ADP, epinephrine, ristocetin and the like) on the effects and related functions of platelets, and can also be used for monitoring the conventional antiplatelet treatment.
Description
Technical Field
The invention belongs to the technical field of medical biology, and relates to a polypeptide, in particular to a polypeptide A11 for resisting platelet aggregation, a preparation method thereof, a pharmaceutical composition comprising the polypeptide A11 as an active ingredient, and an application of the polypeptide A11 in preparation of antiplatelet drugs.
Background
The incidence, mortality, disability rate and recurrence rate of the cardiovascular and cerebrovascular disease thrombosis events are high year by year, which not only brings heavy economic burden to patients, but also causes certain damage to the physiology and psychology of the patients, and leads to the reduction of the life quality of the patients. Activation of platelets is a central link in thrombosis and therefore antiplatelet therapy is important in the management of cardiovascular disease. At present, clinical antiplatelet drugs still have the defects of bleeding risk, individual difference of curative effect, drug resistance and the like. Therefore, the search for safer and more effective antiplatelet drugs with stronger targeting effect is the key point to be solved urgently in antiplatelet research.
The platelet membrane receptor PAR1 is an important regulator of thrombin interaction with platelets to platelet activation and thrombosis. Proteolysis of the N-terminus of PAR-1 exposes the extracellular thrombin binding site, which binds to thrombin, thereby inducing a clotting response. Inhibition of thrombin-mediated platelet activation is an important target for development of antiplatelet drugs. For example, the PAR1 competitive antagonist vallaparsone is approved in the united states as an adjunctive antiplatelet agent in patients with acute coronary syndrome, and is also a secondary prophylactic agent for vascular events in patients with myocardial infarction or peripheral arterial disease. However, clinical trials show that while inhibiting platelet aggregation, vorapazamide also increases the risk of cerebral hemorrhage in patients.
At present, no report of the polypeptide A11 for resisting platelet aggregation and the activity thereof exists in the prior art.
Disclosure of Invention
The invention aims to provide an anti-platelet aggregation polypeptide A11, a preparation method thereof, a pharmaceutical composition comprising the same as an active ingredient, and application thereof in preparation of anti-platelet drugs.
In order to achieve the above purpose of the present invention, the present invention provides the following technical solutions:
an anti-platelet aggregation polypeptide A11 is composed of 12 amino acid sequences shown by Ser-Ile-Ser-Ser-Asn-Asn-Ser-Asn-Pro-Val-Glu-Asp, has an amino acid sequence shown by SEQ ID NO. 1 in a sequence table, and has a molecular weight of 1262.24.
The invention also provides application of the anti-platelet aggregation polypeptide A11 in preparation of preparations with platelet aggregation inhibition effect.
And the application of the polypeptide A11 for resisting platelet aggregation in preparing medicaments for resisting platelet aggregation.
And the application of the anti-platelet aggregation polypeptide A11 in preparing medicaments for treating cardiovascular diseases.
According to the application of the polypeptide A11 in preparing the medicines for resisting platelet aggregation or treating cardiovascular diseases, the polypeptide A11 can achieve the effect of resisting platelet aggregation through the remarkable inhibition effect of collagen-induced human platelet aggregation and thrombin-induced platelet clot retraction.
According to the application of the polypeptide A11 in preparing a medicament for resisting platelet aggregation or treating cardiovascular diseases, the polypeptide A11 can obviously inhibit 0.2U/mL thrombin-induced clot retraction at 1 mM.
According to the application of the polypeptide A11 in preparing the medicines for resisting platelet aggregation or treating cardiovascular diseases, the polypeptide A11 can obviously inhibit platelet aggregation induced by collagen, and the inhibition efficiency is dose-dependent.
The invention also provides a pharmaceutical composition, which comprises a therapeutically effective amount of the polypeptide A11 for resisting platelet aggregation and a pharmaceutically acceptable carrier.
The polypeptide A11 related by the invention consists of 12 amino acids, the molecular weight is 1262.24, and the sequence is as follows: Ser-Ile-Ser-Ser-Asn-Asn-Ser-Asn-Pro-Val-Glu-Asp. Experiments show that A11 significantly inhibits thrombin-induced platelet aggregation and clot retraction. Therefore, A11 can be used for the development of antiplatelet drugs. A11 can also be made into composition with one or more pharmaceutically acceptable carriers, and can be used for preparing antiplatelet antithrombotic medicines.
When the polypeptide A11 of the present invention is used as a medicine, it can be used as it is or in the form of a pharmaceutical composition. The pharmaceutical composition contains 0.1-99%, preferably 0.5-90% of the compound of the present invention, the balance being pharmaceutically acceptable, pharmaceutically acceptable carriers and/or excipients that are non-toxic and inert to humans and animals.
The pharmaceutically acceptable carrier or excipient is one or more of solid, semi-solid and liquid diluents, fillers and pharmaceutical adjuvants. The pharmaceutical composition of the present invention is used in the form of a dose per unit body weight. The medicine of the present invention may be administrated through injection and oral taking.
Compared with the prior art, the invention has the advantages that:
1. the invention newly invents the polypeptide A11, develops new medical application of the polypeptide A11 and develops a new application field.
2. The polypeptide A11 of the invention has the advantages of low price, no toxic or side effect, simple preparation process, capability of being made into oral dosage forms, injection dosage forms, tablets and the like, and convenient use.
3. The polypeptide A11 of the invention can obviously inhibit the retraction of blood clots induced by thrombin. Can effectively inhibit platelet aggregation and can be effectively used as an antiplatelet medicament.
4. The product polypeptide A11 of the invention can obviously inhibit platelet aggregation induced by collagen, and the inhibition efficiency is dose-dependent. Can effectively inhibit platelet aggregation and can be effectively used as an antiplatelet medicament.
Drawings
FIG. 1 is a high performance liquid chromatography purification diagram of a polypeptide provided by the present invention: the peak value C is the purified polypeptide A11.
FIG. 2 is a secondary mass spectrometric identification of peak C (polypeptide A11) of FIG. 1.
FIG. 3 is a graph of the effect of polypeptide A11 on thrombin-induced platelet aggregation;
FIG. 4 is a bar graph of the effect of polypeptide A11 on thrombin-induced platelet aggregation;
FIG. 5 is a graph showing the effect of polypeptide A11 on thrombin-induced platelet clot retraction.
Detailed Description
The following describes embodiments of the present invention in more detail with reference to the accompanying drawings and specific examples. However, the present invention is not limited thereto.
Example 1
Polypeptide A11 was synthesized using the method of solid phase polypeptide synthesis according to the methods reported in the literature (La Face DM, Couture C, Anderson K, et al. differential T cell signaling induced by anti-inflammatory peptides-MHC complexes and the associated proteinaceous responses. J Immunol.1997Mar 1; 158(5): 2057-2064.). The synthesized polypeptide is purified by High Performance Liquid Chromatography (HPLC) to obtain a concentration of 95% or more (figure 1). Subsequent amino acid sequence and molecular weight determinations were made by Mass Spectrometry (MS), which identified the synthesized polypeptide as a11 (fig. 2).
A11 inhibits thrombin-induced human platelet aggregation in vitro.
(1) The platelet-derived healthy volunteers of the experimental people sign blood donation informed consent and give certain nutritional supplement. Collecting venous whole blood, separating single blood collecting platelet from Kunming blood center, and collecting single blood collecting platelet from Hemopoliaceae of Kunming medical university.
(2) The specific implementation mode is as follows:
step one, DMSO is adopted to dissolve and adjust the concentration of A11 to 400mM and 200 mM.
And step two, washing the blood platelets. 1mL of human apheresis platelets which are stored in a constant-temperature shaking manner at 25 ℃ are taken to be put into a 1.5mL centrifuge tube, EDTA with the final concentration of 5mM and 0.1U/mL of Apyrase (prepared by physiological saline to prevent platelet aggregation in the centrifugation process) are added, and 400g of the platelet is centrifuged for 10 minutes at room temperature; after centrifugation, the supernatant was discarded from human apheresis, and 1mL of Tyrode's Buffer B (137mM NaCl,27mM KCl,1mM MgCl) was added to the cell pellet2，0.42mM NaH2PO45.5mM Glucose,5.55mM HEPES, 0.25% bone Serum Albumin, pH 6.5), 5mM EDTA, 0.1U/mL Apyrase, gently blown, 400g at room temperature for another 10 minutes; using Tyrode's Buffer A (137mM NaCl,27mM KCl,1mM MgCl)2,0.42mM NaH2PO45.5mM Glucose,5.55mM HEPES, 0.25% bone Serum Albumin, pH 7.4) resuspension centrifugationThe platelet count of the latter platelets was adjusted to 150-9And L. The platelets were stored at 70rpm with shaking at 25 ℃ and used within 1 hour after washing.
And step three, sucking 400 mu L of washing platelet resuspension and preheating for 5min at 37 ℃. A11 was added to the experimental group at final concentrations of 1mM and 2mM, and an equal volume of DMSO was added to the positive control group (Vehicle), and the incubation was carried out for 20min at 37 ℃. Opening the platelet aggregation instrument, setting parameters according to requirements, putting a magnetic rod into the incubated washed platelets, inserting a platelet reaction cup with a magnetic stirring rod into a detection hole of a machine, putting the platelet reaction cup into a test area of the platelet aggregation instrument, adjusting zero, adding thrombin, observing the influence of A11 on platelet aggregation caused by an activator at 37 ℃ and 1200rpm for 5-10min in total. And drawing a corresponding bar chart and a corresponding bar chart according to the platelet aggregation curve recorded by the platelet aggregation instrument. Experimental data were statistically analyzed using GraphPadPrism 8.0 software. Group-to-group comparisons were performed using Student's t-test statistical methods. P <0.05 considered the difference to be statistically significant.
As shown in figure 3 of the specification: human washed platelets were incubated with different concentrations of A11 or DMSO at 37 ℃ for 20 minutes, thrombin (0.05U/mL) was added to activate the platelets, and a platelet aggregation curve was plotted and recorded using a platelet aggregometer. The abscissa is the time of the aggregation curve and the ordinate is the real-time aggregation rate of platelets by the platelet aggregometer. A representative platelet aggregation rate curve from the aggregation experiment is presented in fig. 3. At the beginning of the aggregation experiment, the platelet aggregation rate was 0%, thrombin was added immediately, and the platelets in the positive control (Vehicle) group began to aggregate when the experiment proceeded for about 30 seconds. When the aggregation experiment is carried out to about 5 minutes, the aggregation rate of the Vehicle group reaches about 80 percent, the aggregation rate of the 1mM A11 experiment group reaches about 20 percent, and the aggregation rate of the 2mM A11 experiment group reaches about 3 percent. The attached figure 4 of the specification shows: histogram comparing platelet aggregation peaks of Vehicle and different concentrations of group a11(1mM, 2 mM). Six replicates of each group of Vehicle and different concentrations of a11(1mM, 2mM) showed peaks of platelet aggregation as mean ± standard error, which indicates that the differences were statistically significant, where x, x respectively indicate p < 0.001 and p < 0.0001 compared to the Vehicle group. As can be seen from fig. 3 and 4: a11 can obviously inhibit platelet aggregation induced by collagen, and the inhibition efficiency is dose-dependent.
Example 2
A11 inhibited platelet clot retraction.
(1) The source of experimental human platelets was the same as in example 1.
(2) The specific implementation mode is as follows:
platelet rich plasma was diluted with Tyrode's Buffer A and quantified at 500X 109at/L, 200. mu.L of platelet-rich plasma was placed in a siliconized clear glass tube and incubated at 37 ℃ for 20 minutes. A11 was dissolved in DMSO and adjusted to a concentration of 200 mM. The experimental groups are: a positive Control group (Thrombin 0.2U/mL), a negative Control group (Control) and an A11 experimental group. A11 was added to the test group at a final concentration of 1mM, and DMSO was added to the positive control group and the negative control group at an equal volume to the test group, followed by incubation at 37 ℃ for 20 minutes. After incubation, thrombin was added to the positive control and A11 tubes to a final concentration of 0.2U/mL, mixed well and then photographed every 5 minutes at 37 ℃. And observing the retraction speed of the blood clots of each experimental group and the control group and the size difference of the blood clots. The above test groups were repeated 3 times per group.
As shown in figure 5 of the specification: within 35 minutes of experimental monitoring, the Control group platelet suspension did not produce blood clots and retraction of blood clots without thrombin stimulation. In the positive control group (Thrombin 0.2U/mL), the platelet suspension coagulated into a clot and retracted beginning at the 10 th minute of the experiment and ending at a minimum at 30 minutes. In the 1mM A11 test group, the platelet suspension did not clot as a clot, and no significant retraction was seen within 35 minutes of the experiment. Fig. 5 is a representative picture of a repeat experiment, and similar results are obtained in 3 experiments. Thus, 1mM A11 significantly inhibited 0.2U/mL thrombin-induced clot retraction.
Example 3
Dissolving polypeptide A11 in DMSO, adding water for injection, fine filtering, packaging, and sterilizing to obtain injection.
Example 4
Dissolving polypeptide A11 in DMSO, dissolving in sterile water for injection, stirring to dissolve, filtering with sterile filter funnel, performing sterile fine filtration, packaging in ampoule, freeze drying at low temperature, and sealing by aseptic melting to obtain powder for injection.
Example 5
Taking the polypeptide A11, adding excipient according to the weight ratio of 9:1 of the polypeptide A11 to the excipient, and preparing into powder.
Example 6
Taking the polypeptide A11, adding excipient according to the weight ratio of the polypeptide A11 to the excipient of 5:1, granulating and tabletting.
Example 7
Taking the polypeptide A11, and preparing into oral liquid according to conventional oral liquid preparation method.
Example 8:
taking the polypeptide A11, adding excipient according to the weight ratio of the polypeptide A11 to the excipient of 5:1, and making into capsule.
Example 9:
taking the polypeptide A11, adding excipient according to the weight ratio of the polypeptide A11 to the excipient of 3:1, and making into capsule.
The scope of the present invention is not limited to the above-described embodiments, which are intended to help explain and illustrate the present invention, but not to limit the scope of the present invention, if it is designed to be the same as or substituted by the equivalent design of the present invention, and fall within the scope of the present invention as claimed.
Sequence listing of the invention
The invention name is as follows: polypeptide and application thereof in preparation of platelet aggregation resisting medicines
<110> first subsidiary hospital of Kunming medical university
<120> polypeptide and application thereof in preparation of platelet aggregation resistant drugs
<210> 1
<211> 12
<212> PRT
<213> polypeptide A11
<400> 1
Ser Ile Ser Ser Asn Asn Ser Asn Pro Val Glu Asp
1 5 10
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110664292.9A CN113354713B (en) | 2021-06-16 | 2021-06-16 | Polypeptide and application thereof in preparation of platelet aggregation resisting medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110664292.9A CN113354713B (en) | 2021-06-16 | 2021-06-16 | Polypeptide and application thereof in preparation of platelet aggregation resisting medicines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113354713A true CN113354713A (en) | 2021-09-07 |
| CN113354713B CN113354713B (en) | 2022-07-26 |
Family
ID=77534421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110664292.9A Active CN113354713B (en) | 2021-06-16 | 2021-06-16 | Polypeptide and application thereof in preparation of platelet aggregation resisting medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113354713B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117143194A (en) * | 2023-11-01 | 2023-12-01 | 北京大学第一医院 | Anti-platelet aggregation polypeptide, preparation method and application thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0040149A1 (en) * | 1980-05-12 | 1981-11-18 | Choay S.A. | Oligopeptides with specific inhibiting properties of collagen induced aggregation, process for preparing the same and pharmaceutical compositions containing them |
| CN101514231A (en) * | 2008-12-26 | 2009-08-26 | 重庆大学 | Targeted antithrombotic fusion protein and its preparation method and application |
| US20100260828A1 (en) * | 2008-11-03 | 2010-10-14 | The Board Of Trustees Of The University Of Illinois | Modulation of Platelet Aggregation |
| WO2010129890A2 (en) * | 2009-05-08 | 2010-11-11 | Virginia Tech Intellectual Properties, Inc. | Compounds and methods for inhibiting platelet aggregation |
| CN102241734A (en) * | 2011-04-15 | 2011-11-16 | 广东医学院 | Anticoagulation polypeptide and application thereof |
| CN102391360A (en) * | 2011-11-02 | 2012-03-28 | 东南大学 | Small peptide capable of resisting thrombosis and platelet aggregation |
| CN108503688A (en) * | 2017-07-10 | 2018-09-07 | 昆明医科大学第附属医院 | A kind of polypeptide of platelet aggregation-against |
| CN111487411A (en) * | 2019-01-29 | 2020-08-04 | 广州瑞博奥生物科技有限公司 | New applications of CEACAM1 polypeptides |
| CN112125953A (en) * | 2020-07-23 | 2020-12-25 | 昆明医科大学第一附属医院 | Polypeptide for resisting platelet aggregation |
-
2021
- 2021-06-16 CN CN202110664292.9A patent/CN113354713B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0040149A1 (en) * | 1980-05-12 | 1981-11-18 | Choay S.A. | Oligopeptides with specific inhibiting properties of collagen induced aggregation, process for preparing the same and pharmaceutical compositions containing them |
| US20100260828A1 (en) * | 2008-11-03 | 2010-10-14 | The Board Of Trustees Of The University Of Illinois | Modulation of Platelet Aggregation |
| CN101514231A (en) * | 2008-12-26 | 2009-08-26 | 重庆大学 | Targeted antithrombotic fusion protein and its preparation method and application |
| WO2010129890A2 (en) * | 2009-05-08 | 2010-11-11 | Virginia Tech Intellectual Properties, Inc. | Compounds and methods for inhibiting platelet aggregation |
| CN102241734A (en) * | 2011-04-15 | 2011-11-16 | 广东医学院 | Anticoagulation polypeptide and application thereof |
| CN102391360A (en) * | 2011-11-02 | 2012-03-28 | 东南大学 | Small peptide capable of resisting thrombosis and platelet aggregation |
| CN108503688A (en) * | 2017-07-10 | 2018-09-07 | 昆明医科大学第附属医院 | A kind of polypeptide of platelet aggregation-against |
| CN111487411A (en) * | 2019-01-29 | 2020-08-04 | 广州瑞博奥生物科技有限公司 | New applications of CEACAM1 polypeptides |
| CN112125953A (en) * | 2020-07-23 | 2020-12-25 | 昆明医科大学第一附属医院 | Polypeptide for resisting platelet aggregation |
Non-Patent Citations (3)
| Title |
|---|
| MEIMEI CHEN等: "A novel direct factor Xa inhibitory peptide with anti-platelet aggregation activity from Agkistrodon acutus venom hydrolysates", 《SCIENTIFIC REPORTS》 * |
| 孟照辉等: "血小板相关活性肽的研究进展", 《临床医学》 * |
| 王晓霞等: "AoGDW肽抑制血小板聚集的作用机制", 《中国药理学通报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117143194A (en) * | 2023-11-01 | 2023-12-01 | 北京大学第一医院 | Anti-platelet aggregation polypeptide, preparation method and application thereof |
| CN117143194B (en) * | 2023-11-01 | 2024-02-06 | 北京大学第一医院 | Anti-platelet aggregation polypeptide, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113354713B (en) | 2022-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101034133B1 (en) | Extracts for the prevention or treatment of thrombotic diseases | |
| JP2005041881A (en) | Therapeutic use of actin-binding compounds | |
| JPH07503231A (en) | Therapeutic inhibition of platelet aggregation by nucleophile/nitric oxide complexes and their derivatives | |
| WO2013063928A1 (en) | Small peptide for resisting thrombus and platelet aggregation | |
| CN113354713A (en) | Polypeptide and application thereof in preparation of platelet aggregation resisting medicines | |
| CN113429457A (en) | Polypeptide for resisting platelet aggregation and application thereof | |
| JP7612025B2 (en) | Pharmaceutical composition for treating sepsis and its use | |
| CN1112198C (en) | Thrombolytic medicine and its preparation and use | |
| JPH06234636A (en) | Use of leflunomide for inhibiting interleukin-8 | |
| CN113429459A (en) | Anti-platelet polypeptide, pharmaceutical composition thereof and application thereof | |
| JPH0114206B2 (en) | ||
| CN103083302B (en) | Salvianolic acid A compositions is for the preparation of the purposes of protection ischemic tissue of brain damage medicine | |
| WO1998024467A1 (en) | Remedies for fulminant hepatitis | |
| CN106822090B (en) | Application of 3,4,7-trihydroxyisoflavone or 3-methoxydaidzein in the preparation of drugs for inhibiting platelet aggregation and thrombosis | |
| CN104055763B (en) | Application of the glycine on the drug for preparing the intravascular hemolysis that prevention puerarin injection induces | |
| CN115819500A (en) | An anti-platelet aggregation-penetrating polypeptide and its application | |
| JP2019089722A (en) | Method of producing platelet rich plasma | |
| JPH0424331B2 (en) | ||
| CN113244225B (en) | Application of pseudolaric acid B in preparation of antiplatelet drugs | |
| CN105561309B (en) | A kind of pharmaceutical composition and its preparation method and application containing ginkolide B and thrombin inhibitor | |
| CA3171287A1 (en) | Medical use of icaritin | |
| CN103301104B (en) | Salvianolic acid A compositions is for the preparation of the purposes saving cerebral ischemic penumbra medicine | |
| HK40081397A (en) | Medical use of anyhdroicaritin | |
| US20180305409A1 (en) | Multi-target compound with anticoagulation and antiplatelet activity, preparation method therefor, and use thereof | |
| CN105456256A (en) | Medicinal composition containing bilobalide B and vitamin K antagonist as well as preparation method and application of medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 295 Xichang Road, Xishan District, Kunming City, Yunnan Province Patentee after: The First Affiliated Hospital of Kunming Medical University (Yunnan Dermatology Hospital) Country or region after: China Address before: 295 Xichang Road, Xishan District, Kunming City, Yunnan Province Patentee before: FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL University Country or region before: China |
|
| CP03 | Change of name, title or address | ||
| OL01 | Intention to license declared | ||
| OL01 | Intention to license declared | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210907 Assignee: Kunming Exosome Technology Co.,Ltd. Assignor: The First Affiliated Hospital of Kunming Medical University (Yunnan Dermatology Hospital) Contract record no.: X2025980006773 Denomination of invention: A peptide and its application in the preparation of antiplatelet aggregation drugs Granted publication date: 20220726 License type: Open License Record date: 20250403 |
|
| EE01 | Entry into force of recordation of patent licensing contract |